PRKCI and neoplasm: Another recent study demonstrated that an agonist of CD40 (another co-stimulatory activator of T cells), in combination with inhibitors of MEK and autophagy, activated anti-tumor immunity and inhibited PDAC growth in a mouse model [84] indicating the potential relevance of therapeutically targeting PKCι.